The LuTectomy trial has just been published in European Urology, and as the GU Cast team have been very much involved, we thought we should dive into the details on today's podcast. LuTectomy is a clinical trial to evaluate the role of 177-Lutetium-PSMA prior to radical prostatectomy. Declan is the study co-PI along with Professor Michael Hofman, and Renu is first author on the LuTectomy paper (and doing a PhD on it)! Plus, Professor Ken Herrmann from Essen has co-authored the accompanying Editorial in European urology and joins us for a discussion.

Even better on our YouTube channel

Thanks to all the LuTectomy team and to all of our fantastic patients. And huge thanks to our funders.

Funding/Support:
This investigator-initiated study was funded by the Movember Foundation, the Australian Government Medical Research Future Fund (MRFF) with contribution from the EJ Whitten Foundation and Novartis.

Acknowledgements:
We thank the medical, surgical, nursing, nuclear medicine, and administrative staff of all the departments at the Peter MacCallum Cancer Centre who were involved in this trial. We thank the patients who agreed to participate in the study. PSMA-617 was supplied
 by Novartis and no carrier added 177Lu by the Australian Nuclear Science and Technology Organisation (ANSTO).
We remember and thank the late Dr John Violet for his involvement including study conception and design.

Links:
LuTectomy paper in European Urology
LuTectomy Editorial